Mitochon Pharmaceuticals Granted EMA Authorisation for Neurogenerative Biomarker Research

Mitochon Pharmaceuticals has been given authorisation by the European Medicines Agency to start early-stage biomarker research in order to aid individuals with managing neurogenerative conditions.   

The clinical trial will explore MP101, an oral treatment that focuses on mitochondrial function, recruiting individuals with amyotrophic lateral sclerosis and Alzheimer’s, amongst other neurogenerative conditions, to assess the treatment’s reliability and possible alterations in disease-specific biomarkers. 

According to data, MP-101 shortens the length of seizures while maintaining brain capacity, medium spiny neurons, and limb mobility.   

John Geisler, the leading scientific executive at Mitochon, stated, “We are delighted for the opportunity to explore this provocative idea that most, if not all, neurodegenerative diseases are rooted in mitochondrial dysfunction.” 

Geisler went on to add, “We predict that chronic treatment with this unique platform, at micro-doses, will resolve mitochondrial issues and change important disease-specific biomarkers in all four indications similarly.”   

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.